Page last updated: 2024-09-03

ym 264 and ticlopidine

ym 264 has been researched along with ticlopidine in 1 studies

Compound Research Comparison

Studies
(ym 264)
Trials
(ym 264)
Recent Studies (post-2010)
(ym 264)
Studies
(ticlopidine)
Trials
(ticlopidine)
Recent Studies (post-2010) (ticlopidine)
90010,2891,8934,671

Protein Interaction Comparison

ProteinTaxonomyym 264 (IC50)ticlopidine (IC50)
Alpha-2A adrenergic receptorHomo sapiens (human)0.382
Cytochrome P450 2D6Homo sapiens (human)6.2928
Alpha-2B adrenergic receptorHomo sapiens (human)0.304
Alpha-2C adrenergic receptorHomo sapiens (human)1.175
Cytochrome P450 2B6Homo sapiens (human)0.405
Cytochrome P450 2C19Homo sapiens (human)0.6678
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.426

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Horie, M; Mase, T; Nagaoka, H; Sakurai, Y; Tomioka, K; Yamada, T1

Other Studies

1 other study(ies) available for ym 264 and ticlopidine

ArticleYear
Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat.
    Biochemical and biophysical research communications, 1991, Apr-30, Volume: 176, Issue:2

    Topics: Animals; Azepines; Disease Models, Animal; Glomerulonephritis, Membranous; Hypercholesterolemia; Male; Metabolic Clearance Rate; Methylprednisolone; Piperazines; Platelet Activating Factor; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidines; Ticlopidine; Triazoles

1991